Travere reported Filspari net product sales up year-on-year, with contribution from its Tiopronin products. Learn why TVTX ...

Travere Therapeutics (TVTX) drew investor attention on 4 August 2026 after reporting second quarter results that combined ...

Earlier this week, Travere Therapeutics reported Q2 2026 results showing revenue rising to US$169.58 million from US$114.45 ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Travere Therapeutics, Inc. (TVTX) on Tuesday reported a loss of $34.8 million in its second quarter. The San Diego-based company said it had a loss of 37 cents per ...

(Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conf ...

Travere Therapeutics stock has delivered a very strong 341.0% return over the past five years, and the current valuation ...

Q2 reframed FILSPARI as a two-indication commercial story, with management emphasizing it was "the first quarter with FILSPARI commercially available across both IgA nephropathy and FSGS" (President, ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its second quarter 2026 financial results and provided a corporate update. “With an exceptional second quarter, Travere has entered a new ...

3 Under-the-Radar Healthcare Companies Travere Therapeutics (NASDAQ:TVTX) reported second-quarter results marked by record ...

Travere Therapeutics Inc. TVTX shares surged 13.44% to $63.55 in after-hours trading on Tuesday after the biopharmaceutical ...

HONG KONG, July 8, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaboration agreement with Travere Therapeutics, ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.